琥珀酸索利那新治疗经尿道前列腺双极等离子电切术后膀胱痉挛的疗效观察

目的观察琥珀酸索利那新对经尿道前列腺双极等离子电切术后膀胱痉挛的治疗效果,并对其耐受性进行评价。方法采用随机、双盲的方法将65例经尿道前列腺双极等离子电切术后膀胱痉挛频繁发作患者分为治疗组和对照组,治疗组口服琥珀酸索利那新5mg,1次/d,对照组口服酒石酸托特罗定片2mg,2次/d治疗。结果治疗组在术后膀胱痉挛次数(1.87±1.45 VS 2.98±1.24)次、膀胱痉挛平均持续时间(35.2±12.5 VS 54.3±26.8)h、膀胱冲洗转清时间(21.5±4.5 VS 32.4±5.7)h及痉挛程度平均分级(1.58±0.72 VS 2.03±0.75)级,均少于对照组,差异有统计学意义。结论琥珀酸索利那新治疗经尿道前列腺双极等离子电切术后膀胱痉挛有效且安全。

Solifenacin vesicare for bladder spasm after transurethral resection of prostate using plasma kinetic energy

Objective To observe and evaluate the efficacy of solifenacin vesicare on bladder spasm after transurethral resection of prostate using plasma kinetic energy.Methods A randomized,double-blind parallel-controlled sdudy was carried out in 65 patients with bladder spasm after transurethral resection of prostate using plasma kinetic energy.Patients received either solifenacin vesicare(5 mg daily) or Tolterodine(2mg second daily).Results In 72 hours of treatment after operation,the targets of treatment group are lower significantly than those of control group in the mean times of bladder spasm(1.87±1.45 VS 2.98±1.24),length of time(35.2±12.5 VS 54.3±26.8),the time of bladder irrigation(21.5±4.5 VS 32.4±5.7) and the mean grade of bladder spasm(1.58±0.72 VS 2.03±0.75).No severe adverse events occurred in the treatment group.Conclusion The solifenacin vesicare therapy for patients with bladder spasm after transurethral resection of prostate using plasma kinetic energy is effective and safe.